CVSI insider filings
CV Sciences, Inc. — 28 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen CVSI transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 17 legs across 3 filings by 1 insider — 13,212,453 shares, $189,533 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 1,830,000 shares @ $0.02 ($36,600) by CHEEVER CHARLIE E III, filed 2026-09-09.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| CHEEVER CHARLIE E III — 10% owner | 3 | 17 legs · 13,212,453 sh · $189,533 | — | — |
Recent insider filings — CV Sciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | CHEEVER CHARLIE E III — 10% owner | Purchase (P): 1,628,093 @ $0.01 · Purchase (P): 402,618 @ $0.01 | EDGAR |
| 2026-11-16 | 4 | CHEEVER CHARLIE E III — 10% owner | Purchase (P): 1,500,244 @ $0.01 · Purchase (P): 1,076,508 @ $0.01 · Purchase (P): 500,000 @ $0.01 · Purchase (P): 1,980,969 @ $0.01 · Purchase (P): 383,205 @ $0.01 | EDGAR |
| 2026-09-09 | 4 | CHEEVER CHARLIE E III — 10% owner | Purchase (P): 91,387 @ $0.02 · Purchase (P): 749,000 @ $0.02 · Purchase (P): 335,000 @ $0.02 · Purchase (P): 272,500 @ $0.02 · Purchase (P): 470,075 @ $0.02 · Purchase (P): 1,830,000 @ $0.02 · +4 more | EDGAR |
| 2025-02-20 | 4 | Corroon James Michael Jr. — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Grasser Joerg — Chief Financial Officer | Grant/award (A): 2,350,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Dowling Joseph D — Chief Executive Officer, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | McCorkle William — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | McCorkle William — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Corroon James Michael Jr. — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Grasser Joerg — Chief Financial Officer | Grant/award (A): 2,350,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Dowling Joseph D — Chief Executive Officer, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Dowling Joseph D — CEO, Director | Grant/award (A): 2,500,000 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Grasser Joerg — CFO | Grant/award (A): 1,250,000 (derivative) @ $0 | EDGAR |
| 2022-11-07 | 4 | McCorkle William — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2022-08-15 | 4 | Corroon James Michael Jr. — Director | Grant/award (A): 500,000 (derivative) @ $0.03 | EDGAR |
| 2022-04-01 | 4 | Grasser Joerg — CFO | Disposition to issuer (D): 750,000 (derivative) · Disposition to issuer (D): 750,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) | EDGAR |
| 2022-04-01 | 4 | Dowling Joseph D — CEO, Director | Disposition to issuer (D): 1,500,000 (derivative) · Disposition to issuer (D): 1,500,000 (derivative) · Disposition to issuer (D): 500,000 (derivative) · Disposition to issuer (D): 500,000 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · +4 more | EDGAR |
| 2021-06-03 | 4 | Altman Elizabeth Ann — Director | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | MAROON JOSEPH C MD — Director | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | BLAKE PAUL — Director | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | GRAHAM TERRI F — Director | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2021-05-24 | 4 | MAROON JOSEPH C MD — Director | Purchase (P): 50,000 @ $0.38 | EDGAR |
| 2021-03-11 | 4 | Dowling Joseph D — CEO, Director | Grant/award (A): 1,500,000 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Grasser Joerg — CFO | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | MacKay Douglas Jesse — Sr VP Scientific/Regulatory | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2021-02-09 | 4 | Mona Michael Joseph Jr — 10% owner | Sale (S): 100,000 @ $0.61 · Sale (S): 100,000 @ $0.63 · Sale (S): 16,600 @ $0.66 | EDGAR |
| 2021-01-19 | 4 | Mona Michael Joseph Jr — 10% owner | Sale (S): 75,000 @ $0.56 · Sale (S): 75,140 @ $0.57 | EDGAR |
| 2020-12-08 | 4 | Mona Michael Joseph Jr — 10% owner | Sale (S): 400,000 @ $0.59 · Sale (S): 57,400 @ $0.61 · Sale (S): 42,800 @ $0.61 | EDGAR |
Recent 8-K events — CV Sciences, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-26 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CVSI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs